Sartorius Stedim Biotech: share price rises thanks to Barclays

(CercleFinance.com) - Sartorius Stedim Biotech was one of the biggest risers in the SBF 120 index on Wednesday morning on the Paris Bourse, buoyed by a recommendation upgrade by Barclays analysts.


In a note, the research firm hails the emergence of a "new world" for the pharmaceutical and biopharmaceutical manufacturing industry, of which Sartorius Stedim Biotech is one of the two leading specialists in Europe, along with its parent company Sartorius.

According to its calculations, the sector is now only one quarter away from a return to the normal trajectory that would have characterized it without the emergence of Covid.

Despite this, both Sartorius Stedim Biotech and Sartorius are trading at much lower valuation levels than their peers, points out Barclays, which has accordingly raised its recommendation on Sartorius Stedim Biotech from 'in-line weighted' to 'overweight', with a price target raised from €200 to €250.

The share price rose by over 2.5% on Wednesday morning in the wake of these comments.

Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.